---
document_datetime: 2025-12-29 08:15:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/eladynos-0.html
document_name: eladynos-0.html
version: success
processing_time: 0.066728
conversion_datetime: 2025-12-30 02:33:52.23379
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Eladynos

[RSS](/en/individual-human-medicine.xml/65828)

##### Refused

This medicine has been refused authorisation

abaloparatide Medicine Human Refused

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Eladynos](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Eladynos, intended for the treatment of osteoporosis (a disease that makes bones fragile). The company that applied for authorisation is Radius International Ltd.

The company requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion, and confirmed the refusal of the marketing authorisation on 26 July 2018.

Expand section

Collapse section

## What is Eladynos?

Eladynos is a medicine that contains the active substance abaloparatide. It was to be available as a solution for injection under the skin.

## What was Eladynos expected to be used for?

Eladynos was to be used to treat osteoporosis in women who have been through the menopause and who are at risk of bone fractures, a complication of osteoporosis.

## How does Eladynos work?

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to fracture. In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall.

The active substance in Eladynos, abaloparatide, is similar to part of the human parathyroid hormone. It stimulates bone formation by acting on osteoblasts (bone-forming cells).

## What did the company present to support its application?

The company presented the results of one main study in women who had been through the menopause and who were at risk of fractures. Women received Eladynos or teriparatide (another medicine used to treat osteoporosis) or placebo (a dummy treatment) for 18 months. Measures of effectiveness were the number of new vertebral fractures and the number of non-vertebral fractures (including hip fractures, which can be serious and disabling).

## What were the CHMP's main concerns that led to the refusal?

The CHMP considered that the main study did not satisfactorily show that Eladynos is effective at preventing non-vertebral fractures in women who have been through the menopause.

The data from two of the study sites were not reliable and had to be excluded as the study had not been conducted in compliance with 'good clinical practice' (GCP) at those sites.

From a safety point of view, the CHMP was concerned about the medicine's effects on the heart, such as increases in heart rate and palpitations.

Because most post-menopausal women are at an increased risk of heart problems, the CHMP could not identify a group of patients in whom the benefits would outweigh the risks. Therefore, at that point in time, the Committee was of the opinion that the benefits of Eladynos did not outweigh its risks and recommended that the medicine be refused marketing authorisation. The CHMP refusal was confirmed after re-examination.

## What consequences does this refusal have for patients in clinical trials?

The company informed the CHMP that there are no ongoing clinical trials with Eladynos in Europe.

Questions and answers on refusal of the marketing authorisation for Eladynos (abaloparatide)

Adopted

Reference Number: EMA/504599/2018

English (EN) (71.94 KB - PDF)

**First published:** 23/03/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_en.pdf)

[Other languages (22)](#file-language-dropdown-702)

български (BG) (96.17 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_bg.pdf)

español (ES) (71.74 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_es.pdf)

čeština (CS) (93.08 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_cs.pdf)

dansk (DA) (71.41 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_da.pdf)

Deutsch (DE) (72.14 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_de.pdf)

eesti keel (ET) (71.17 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_et.pdf)

ελληνικά (EL) (97.64 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_el.pdf)

français (FR) (72.18 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_fr.pdf)

hrvatski (HR) (89.2 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_hr.pdf)

italiano (IT) (71.55 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_it.pdf)

latviešu valoda (LV) (92.58 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_lv.pdf)

lietuvių kalba (LT) (93.96 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_lt.pdf)

magyar (HU) (90.29 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_hu.pdf)

Malti (MT) (94.11 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_mt.pdf)

Nederlands (NL) (71.6 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_nl.pdf)

polski (PL) (94.37 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_pl.pdf)

português (PT) (71.7 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_pt.pdf)

română (RO) (90.29 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_ro.pdf)

slovenčina (SK) (92.19 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sk.pdf)

slovenščina (SL) (89.28 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sl.pdf)

Suomi (FI) (71.06 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_fi.pdf)

svenska (SV) (71.54 KB - PDF)

**First published:**

23/03/2018

**Last updated:**

27/07/2018

[View](/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_sv.pdf)

## Product details

Name of medicine Eladynos Active substance abaloparatide International non-proprietary name (INN) or common name abaloparatide Therapeutic area (MeSH) Osteoporosis Anatomical therapeutic chemical (ATC) code H05AA

### Pharmacotherapeutic group

Calcium homeostasis

## Application details

EMA product number EMEA/H/C/004157 Marketing authorisation applicant Radius Health Ireland Ltd Opinion adopted 26/07/2018 Refusal of marketing authorisation 07/01/2019

## Assessment history

Eladynos : EPAR - Refusal public assessment report

Adopted

Reference Number: EMA/CHMP/581111/2018

English (EN) (2.84 MB - PDF)

**First published:** 14/02/2019

[View](/en/documents/assessment-report/eladynos-epar-refusal-public-assessment-report_en.pdf)

#### News on Eladynos

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2018) 27/04/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/02/2019

## Share this page

[Back to top](#main-content)